Percentage of patients aged 18 years or older with a diagnosis of RA AND receiving a first course therapy using a biologic disease-modifying antirheumatic drug (DMARD) who had a prescription for a conventional synthetic (cs) DMARD at least 10 weeks prior to newly initiated biologic therapy during the measurement year.